Study the pathological features of diseases using induced pluripotent stEM cells derived form patient's somatic cells
The limited experimental access to disease-affected human tissues has severely impeded the elucidating of molecular mechanisms underlying disease development. Generation of induced pluripotent stEM cells (iPSCs) by over-expression of defined transcription factors in somatic cells, in particular in those from patient somatic cells, presents an attractive and promising approach to model the early stages of diseases in vitro and to screen novel biomarkers as well as therapeutic medicines. Recently, many research groups have independently reported that patient-specific iPSC-derived cells recapitulated multiple features of pathological events of a particular disease, offering experimental evidence of utilizing patient-specific iPSCs to model diseases and reevaluate the current therapies. We have derived iPSC lines using somatic cells of patients suffering from Klinefelter's Syndrome (KS) and Alzheimer's Disease (AD) and explored the possibility to use these iPSC lines to recapitulate the pathological features of the diseases. Our results show that patient's specific iPSC lines provide good opportunity to study the development and treatment of diseases.
sRNA Induces the Large-scale Transdetermination of Mesenchymal StEM Cells into HEMatopoietic StEM Cells in Human.
Mesenchymal stEM cells (MSCs) can differentiate into cells of bone, endothelium, adipose tissue, cartilage, muscle, and brain. However, whether they can transdeterminate into hEMatopoietic stEM cells (HSCs) rEMains unsolved. We report here that a subpopulation of human MSCs that are CD44+,CD29+, CD105+, CD166+,CD133-,CD34- could differentiate into hEMatopoietic stEM cells (CD150+/CD133+/CD34+) and their descending blood cells in vitro, when transfected with new endogenous shRNAs The sRNA was high-effectively delivered into MSCs by a novel peptide means. These induced MSC-HSCs could form different types of hEMatopoietic colonies as nature-occurring HSCs did. Upon transplantation into sublethally irradiated NOD/SCID mice, these MSC-HSCs engrafted and differentiated into all hEMatopoietic lineages such as erythrocytes, lymphocytes, myelocytes and thrombocyte. More importantly, these induced HSCs could successfully engraft and effectively function in patients with severe aplastic anEMia. Furthermore, we dEMonstrated the first evidence that the transdetermination of MSCs was induced by acetylation of histone proteins and activation of many transcriptional factors. Together, our findings identify the sRNAs that dictates a directed differentiation of MSCs toward HSCs and open up a new source for HSCs used for the treatment of blood diseases and artificial stEM cell-made blood.
Study the pathological features of diseases using induced pluripotent stEM cells derived form patient's somatic cells
The limited experimental access to disease-affected human tissues has severely impeded the elucidating of molecular mechanisms underlying disease development. Generation of induced pluripotent stEM cells (iPSCs) by over-expression of defined transcription factors in somatic cells, in particular in those from patient somatic cells, presents an attractive and promising approach to model the early stages of diseases in vitro and to screen novel biomarkers as well as therapeutic medicines. Recently, many research groups have independently reported that patient-specific iPSC-derived cells recapitulated multiple features of pathological events of a particular disease, offering experimental evidence of utilizing patient-specific iPSCs to model diseases and reevaluate the current therapies. We have derived iPSC lines using somatic cells of patients suffering from Klinefelter's Syndrome (KS) and Alzheimer's Disease (AD) and explored the possibility to use these iPSC lines to recapitulate the pathological features of the diseases. Our results show that patient's specific iPSC lines provide good opportunity to study the development and treatment of diseases.
Paul RothEMund详细讲述 DNA 折叠
2007年,Paul RothEMund 给TED做了一个关于他自己研究方向,DNA折叠的概述演讲。这一次,他陈述了大量清楚的细节来描述这一领域的广阔前景——来建造极小的机器并让它们进行自我组装。
Interplays between Mesenchymal StEM Cells and Immune Responses
Mesenchymal stEM cells (MSCs) exist in almost all tissues and are crucial in maintaining the cellular homeostasis of multicellular organisms. They provide the ultimate cell source for tissue repair and regeneration. Under pathological conditions, these cells are awakened, activated, and mobilized to damaged tissue sites. Since tissue damages are often accompanied by inflammatory factors, from both innate immune response and adaptive immune response, it is sensible that MSCs delicately interact with inflammatory factors at the sites of tissue damages.
Depending on the type and persistence of the inflammatory factors, the activated MSCs could lead either to complete or partial tissue repair, or to chronic inflammation and further tissue damage, such as cancer and fibrosis. Indeed, recent studies have shown that there is a bidirectional interaction between MSCs and inflammatory cells and cytokines. However, much information of this information rEMains to be elucidated. Further investigations in this newly EMerging exciting research area will undoubtedly lead to better understanding of pathogenesis of various diseases and novel treatment strategies.
Cell and chEMical biology of mitosis
Cell and chEMical biology of mitosis
Cell and chEMical biology of mitosis
Cell and chEMical biology of mitosis
Targets-based therapy for leukEMia: opportunity and challenge
优点主要为：能增强患者的免疫力，防止肿瘤的转移和复发，对病人机体的损伤小。 在我国，现在普遍开展的树突状细胞（DC）和细胞因子诱导的杀伤细胞（CIK）的生物疗法被广泛应用。